×
About 6,775 results

ALLMedicine™ Myelofibrosis Center

Research & Reviews  2,054 results

Targeting the PI3K pathway in myeloproliferative neoplasms.
https://doi.org/10.1080/14737140.2022.2093192
Expert Review of Anticancer Therapy; Gerds AT, Bartalucci N et. al.

Jun 29th, 2022 - Decreasing efficacy over time or initial suboptimal response to Janus kinase (JAK) inhibitors such as ruxolitinib in a subset of patients, are critical clinical challenges associated with myeloproliferative neoplasms (MPNs), primarily myelofibrosi...

Autoimmune storm following alemtuzumab.
https://doi.org/10.1136/bcr-2021-248037
BMJ Case Reports; Chan C, Beauchemin P et. al.

Jun 28th, 2022 - Alemtuzumab has been associated with the emergence of secondary autoimmune diseases. We report a case of a patient with relapsing-remitting multiple sclerosis who developed a refractory immune thrombocytopaenia associated with vasculitis, myelofib...

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red...
https://clinicaltrials.gov/ct2/show/NCT04717414

Jun 24th, 2022 - Permitted Concomitant Medications and Procedures Subjects are receiving a JAK2 inhibitor for the treatment of MPN-associated MF that is approved in the country where the study is being conducted. JAK2 inhibitors are to be used according to their r...

Optimizing PTCy Dose and Timing
https://clinicaltrials.gov/ct2/show/NCT03983850

Jun 24th, 2022 - Background: Post-transplantation cyclophosphamide (PTCy) reduces rates of severe acute and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT) and safely facilitates human leukocyte antigen (HLA)-hapl...

RR6 prognostic model provides information about survival in myelofibrosis treated with ...
https://doi.org/10.1182/bloodadvances.2022008158
Blood Advances; Scalzulli E, Ielo C et. al.

Jun 24th, 2022 - RR6 prognostic model provides information about survival in myelofibrosis treated with ruxolitinib: validation in a real-life cohort.|2022|Scalzulli E,Ielo C,Luise C,Musiu P,Bisegna ML,|

see more →

Guidelines  4 results

A physician survey on the application of the British Society for Haematology guidelines...
https://doi.org/10.1111/bjh.16390
British Journal of Haematology; Harrison CN, Mead AJ et. al.

Feb 23rd, 2020 - A physician survey on the application of the British Society for Haematology guidelines for the diagnosis and management of myelofibrosis in the UK.|2020|Harrison CN,Mead AJ,Drummond MW,Chiu G,Bains R,|diagnosis,therapy,

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.
https://doi.org/10.6004/jnccn.2017.0157
Journal of the National Comprehensive Cancer Network : JN... Mesa RA, Jamieson C et. al.

Oct 7th, 2017 - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thromboh...

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Onco...
https://doi.org/10.6004/jnccn.2016.0169
Journal of the National Comprehensive Cancer Network : JN... Mesa R, Jamieson C et. al.

Dec 14th, 2016 - Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). The diagn...

Guideline for the diagnosis and management of myelofibrosis.
https://doi.org/10.1111/j.1365-2141.2012.09179.x
British Journal of Haematology; Reilly JT, McMullin MF et. al.

Jun 2nd, 2012 - The guideline group regarding the diagnosis and management of myelofibrosis was selected to be representative of UK-based medical experts, together with a contribution from a single expert from the USA. MEDLINE and EMBASE were searched systematica...

see more →

Drugs  7 results see all →

Clinicaltrials.gov  283 results

Optimizing PTCy Dose and Timing
https://clinicaltrials.gov/ct2/show/NCT03983850

Jun 24th, 2022 - Background: Post-transplantation cyclophosphamide (PTCy) reduces rates of severe acute and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT) and safely facilitates human leukocyte antigen (HLA)-hapl...

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red...
https://clinicaltrials.gov/ct2/show/NCT04717414

Jun 24th, 2022 - Permitted Concomitant Medications and Procedures Subjects are receiving a JAK2 inhibitor for the treatment of MPN-associated MF that is approved in the country where the study is being conducted. JAK2 inhibitors are to be used according to their r...

JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
https://clinicaltrials.gov/ct2/show/NCT02251821

Jun 23rd, 2022 - OUTLINE: PART 1: Patients receive ruxolitinib orally (PO) twice daily (BID) from at least 8 weeks prior to the start of conditioning through day -4 before transplantation, with a taper schedule reducing the dose every 2-3 days beginning after day ...

Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis
https://clinicaltrials.gov/ct2/show/NCT04384692

Jun 23rd, 2022 - OUTLINE: PART 1: Patients receive ruxolitinib orally (PO) starting 8 weeks prior to hematopoietic stem cell transplantation (HSCT) and continuing until approximately 14 days prior to conditioning regimen, then tapered per the treating clinician un...

A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously T...
https://clinicaltrials.gov/ct2/show/NCT03755518

Jun 23rd, 2022 - This is Single-Arm, Open-Label Efficacy and Safety Trial of Fedratinib in Subjects with DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High- Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV M...

see more →

News  358 results

Momelotinib Hits the Mark for Deadly Bone Marrow Cancer
https://www.medscape.com/viewarticle/975651

Jun 15th, 2022 - The investigational drug momelotinib has shown benefits in myelofibrosis in a new phase 3 trial, which could now lead to a Food and Drug Administration approval. This drug had previously shown mixed results in a phase 3 trial funded by Gilead, whi...

Momelotinib hits the mark for deadly bone marrow cancer
https://www.mdedge.com/hematology-oncology/article/255402/cml/momelotinib-hits-mark-deadly-bone-marrow-cancer
Heidi Splete

Jun 13th, 2022 - The investigational drug momelotinib has shown benefits in myelofibrosis in a new phase 3 trial, which could now lead to a Food and Drug Administration approval. This drug had previously shown mixed results in a phase 3 trial funded by Gilead, whi.

Dr. Mesa on the Future of JAK Inhibitor Therapy in Myelofibrosis
https://www.onclive.com/view/dr-mesa-on-the-future-of-jak-inhibitor-therapy-in-myelofibrosis

May 4th, 2022 - Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses the future of JAK inhibitor therapy in myelofibrosis. The addition of more treatment options for myelofibrosis has been a benefit ...

Dr. Verstovsek on Addressing Anemia in Patients with Myelofibrosis
https://www.onclive.com/view/dr-verstovsek-on-addressing-anemia-in-patients-with-myelofibrosis

May 3rd, 2022 - Srdan Verstovsek, MD, PhD, professor, director, Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms, chief, Section for Myeloproliferative Neoplasms, Department of Leukemia, The University of Texas MD Anderson Cancer Center,...

Dr. Verstovsek on the Mechanism of Action of Momelotinib in Myelofibrosis
https://www.onclive.com/view/dr-verstovsek-on-the-mechanism-of-action-of-momelotinib-in-myelofibrosis

May 2nd, 2022 - Srdan Verstovsek, MD, PhD, professor, director, Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms, chief, Section for Myeloproliferative Neoplasms, Department of Leukemia, The University of Texas MD Anderson Cancer Center,...

see more →

Patient Education  4 results see all →